BMP7 and Alzheimer disease: Furthermore, given the recent reports of short-term therapeutic benefit of allogeneic AD-MSCs in refractory LN (Ranjbar et al. 2022), the potential of BMP-7 as adjunctive treatment in this context—given its modulatory role on AD-MSC differentiation already mentioned—should be investigated.